Nancy Yacovzada (@nancyyaco) 's Twitter Profile
Nancy Yacovzada

@nancyyaco

Lady of python, machine learning & causality | PhD from @WeizmannScience | expertise in biomedical data science | red wine, spinning, trance music.

ID: 3011629430

linkhttps://www.linkedin.com/in/nancy-y-1129a223 calendar_today06-02-2015 19:28:05

2,2K Tweet

541 Takipçi

2,2K Takip Edilen

Andrej Karpathy (@karpathy) 's Twitter Profile Photo

# on shortification of "learning" There are a lot of videos on YouTube/TikTok etc. that give the appearance of education, but if you look closely they are really just entertainment. This is very convenient for everyone involved : the people watching enjoy thinking they are

Charlie Kirk (@charliekirk11) 's Twitter Profile Photo

I just debated at Cambridge and Oxford. At Cambridge, instead of focusing on their own decaying country, they are obsessed with Israel. The lack of moral clarity on this topic is chilling. I decided to put this bouncy Brit in his place. Watch:

Ruben Hassid (@rubenhssd) 's Twitter Profile Photo

Apple discovered that these models are not reasoning at all, but instead doing sophisticated pattern matching that works great until patterns become too complex. Then they fall apart like a house of cards.

SightBringer (@_the_prophet__) 's Twitter Profile Photo

Ruben Hassid What you’re seeing here isn’t just a technical paper. It’s a strategic demystification maneuver -an intellectual flare sent up by Apple to reassert narrative sovereignty over AI discourse. Let’s break it with precision: ⸻ 🔍 The Superficial Claim: Large Reasoning Models

Nancy Yacovzada (@nancyyaco) 's Twitter Profile Photo

שינוי מרענן. שמים מוזיקה פרסית ברקע.. #FreeIran שיגור מאיספהאן שלא השלים את הטיסה... תנחשו למה 💪 אבו צאלח הדסק הערבי t.me/salehdesk1

Dr. Dominic Ng (@drdominicng) 's Twitter Profile Photo

DeepMind just dropped a 106-page paper unveiling AlphaGenome. This single model could completely redefine how we discover disease-causing mutations and drug targets. This is massive. 🧵

DeepMind just dropped a 106-page paper unveiling AlphaGenome.

This single model could completely redefine how we discover disease-causing mutations and drug targets.

This is massive. 🧵
Eran Segal (@segal_eran) 's Twitter Profile Photo

Excited to share a milestone published in Nature Medicine from our decade-long effort to build The Human Phenotype Project, a unique longitudinal cohort with unmatched depth of clinical and multi-omic profiling, enabling truly predictive, personalized medicine. Led together with

Excited to share a milestone published in <a href="/NatureMedicine/">Nature Medicine</a> from our decade-long effort to build The Human Phenotype Project, a unique longitudinal cohort with unmatched depth of clinical and multi-omic profiling, enabling truly predictive, personalized medicine.

Led together with
Pablo Corral MD (@drpablocorral) 's Twitter Profile Photo

🧬Could IL-6 signaling be the true therapeutic target behind the smokescreen of hs-CRP? 👉While hs-CRP has long been used as a biomarker of residual inflammatory risk, human genetics suggests it may not be the driver we once thought 👉The IL-6 signaling pathway has emerged as a

🧬Could IL-6 signaling be the true therapeutic target behind the smokescreen of hs-CRP?

👉While hs-CRP has long been used as a biomarker of residual inflammatory risk, human genetics suggests it may not be the driver we once thought

👉The IL-6 signaling pathway has emerged as a
Crémieux (@cremieuxrecueil) 's Twitter Profile Photo

The FDA just updated the approval for Inclisiran—a small-interfering RNA therapy for cholesterol—by making it a front-line therapy. Now, with just two shots a year rather than with daily statin dosing, practically anyone can achieve healthy LDL. Long-acting drugs are winning!

The FDA just updated the approval for Inclisiran—a small-interfering RNA therapy for cholesterol—by making it a front-line therapy.

Now, with just two shots a year rather than with daily statin dosing, practically anyone can achieve healthy LDL.

Long-acting drugs are winning!
Anne Carpenter, PhD (@drannecarpenter) 's Twitter Profile Photo

Have $10M and want to cure some diseases? It costs ~$1B to invent a new medicine…but $10M buys you Project Encore, to see if ANY existing drug might be repurposed for ~100 diseases that have no treatments. Contact me - be a hero for desperate patients! docs.google.com/document/d/1dM…

Have $10M and want to cure some diseases?

It costs ~$1B to invent a new medicine…but $10M buys you Project Encore, to see if ANY existing drug might be repurposed for ~100 diseases that have no treatments.

Contact me - be a hero for desperate patients!
docs.google.com/document/d/1dM…
Epic Plain (@epicplain) 's Twitter Profile Photo

Fibro predict a machine learning risk score for advanced liver fibrosis in the general ... - Nature nature.com/articles/s4159… #MachineLearning

Harrison Hansford (@hjhansford) 's Twitter Profile Photo

🎯 TARGET Guideline published 🎉 TARGET is a reporting guideline for observational studies of interventions that use the target trial framework. Over 3 years it was rigorously developed and was co-published today in JAMA & The BMJ doi.org/10.1001/jama.2…

🎯 TARGET Guideline published 🎉

TARGET is a reporting guideline for observational studies of interventions that use the target trial framework. 

Over 3 years it was rigorously developed and was co-published today in <a href="/JAMA_current/">JAMA</a> &amp; <a href="/bmj_latest/">The BMJ</a> 

doi.org/10.1001/jama.2…
Nancy Yacovzada (@nancyyaco) 's Twitter Profile Photo

One of my favorite works ✨ Not just another research paper left on the shelf, but a model that actually crossed the research–clinic gap. 𝗙𝗶𝗯𝗿𝗼-𝗣𝗿𝗲𝗱𝗶𝗰𝘁 was prospectively validated on real patients, forecasting the likelihood of 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗹𝗶𝘃𝗲𝗿

Dr. Dominic Ng (@drdominicng) 's Twitter Profile Photo

I'm a neuroscientist. "AI psychosis" is constantly in the news. Together with my psychiatry colleague, I reviewed the largest case-series published so far. Here are my thoughts 🧵

I'm a neuroscientist.

"AI psychosis" is constantly in the news. Together with my psychiatry colleague, I reviewed the largest case-series published so far.

Here are my thoughts 🧵